Literature DB >> 20844229

Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR.

Tejal Mehta1, Eric McGrath, Suchitha Bheemreddy, Hossein Salimnia, Nahed Abdel-Haq, Jocelyn Y Ang, Lawrence Lum, Pranatharthi Chandrasekar, George J Alangaden.   

Abstract

Two immunocompromised patients with 2009 H1N1 influenza pneumonia had viral shedding for over 5 weeks despite therapy with oseltamivir. Declining or persistently low cycle threshold values noted on serial qualitative real-time reverse transcriptase PCR (rRT-PCR) of respiratory specimens implied increasing viral load and probable drug resistance. Oseltamivir resistance was later confirmed by pyrosequencing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844229      PMCID: PMC3020826          DOI: 10.1128/JCM.01190-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.

Authors:  Aditya H Gaur; Bindiya Bagga; Subrata Barman; Randall Hayden; Aubrey Lamptey; James M Hoffman; Deepa Bhojwani; Patricia M Flynn; Elaine Tuomanen; Richard Webby
Journal:  N Engl J Med       Date:  2009-12-23       Impact factor: 91.245

2.  H1N1 pneumonitis treated with intravenous zanamivir.

Authors:  I Michael Kidd; Jim Down; Eleni Nastouli; Rob Shulman; Paul R Grant; David Cj Howell; Mervyn Singer
Journal:  Lancet       Date:  2009-09-03       Impact factor: 79.321

3.  The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.

Authors:  Debra Birnkrant; Edward Cox
Journal:  N Engl J Med       Date:  2009-11-02       Impact factor: 91.245

4.  Overview of real-time RT-PCR strategies for quantification of gene rearrangements in the myeloid malignancies.

Authors:  Christophe Picard; Monique Silvy; Jean Gabert
Journal:  Methods Mol Med       Date:  2006

5.  Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-08-21       Impact factor: 17.586

6.  Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Authors:  Margaret Okomo-Adhiambo; Ha T Nguyen; Katrina Sleeman; Tiffany G Sheu; Varough M Deyde; Rebecca J Garten; Xiyan Xu; Michael W Shaw; Alexander I Klimov; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2009-11-13       Impact factor: 5.970

7.  Viral load in patients infected with pandemic H1N1 2009 influenza A virus.

Authors:  Kelvin K W To; Kwok-Hung Chan; Iris W S Li; Tak-Yin Tsang; Herman Tse; Jasper F W Chan; Ivan F N Hung; Sik-To Lai; Chi-Wai Leung; Yat-Wah Kwan; Yu-Lung Lau; Tak-Keung Ng; Vincent C C Cheng; Joseph S M Peiris; Kwok-Yung Yuen
Journal:  J Med Virol       Date:  2010-01       Impact factor: 2.327

  7 in total
  13 in total

1.  Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Authors:  Susu Duan; David A Boltz; Jiang Li; Christine M Oshansky; Henju Marjuki; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

2.  Free-energy simulations reveal that both hydrophobic and polar interactions are important for influenza hemagglutinin antibody binding.

Authors:  Zhen Xia; Tien Huynh; Seung-gu Kang; Ruhong Zhou
Journal:  Biophys J       Date:  2012-03-20       Impact factor: 4.033

Review 3.  Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic.

Authors:  Swati Kumar; Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546.

Authors:  Arnab Basu; Gloria Komazin-Meredith; Courtney McCarthy; Aleksandar Antanasijevic; Steven C Cardinale; Rama K Mishra; Dale L Barnard; Michael Caffrey; Lijun Rong; Terry L Bowlin
Journal:  ACS Infect Dis       Date:  2017-04-03       Impact factor: 5.084

5.  New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Authors:  Arnab Basu; Aleksandar Antanasijevic; Minxiu Wang; Bing Li; Debra M Mills; Jessica A Ames; Peter J Nash; John D Williams; Norton P Peet; Donald T Moir; Mark N Prichard; Kathy A Keith; Dale L Barnard; Michael Caffrey; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

6.  Rapid detection of the H275Y oseltamivir resistance mutation in influenza A/H1N1 2009 by single base pair RT-PCR and high-resolution melting.

Authors:  Steven Y C Tong; Farshid Dakh; Aeron C Hurt; Yi-Mo Deng; Kevin Freeman; Peter K Fagan; Ian G Barr; Philip M Giffard
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

7.  Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis.

Authors:  David N Ku; Sarah K Ku; Beth Helfman; Nael A McCarty; Bernard J Wolff; Jonas M Winchell; Larry J Anderson
Journal:  F1000Res       Date:  2016-08-05

8.  Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir.

Authors:  Irina N Gaisina; Norton P Peet; Han Cheng; Ping Li; Ruikun Du; Qinghua Cui; Kevin Furlong; Balaji Manicassamy; Michael Caffrey; Gregory R J Thatcher; Lijun Rong
Journal:  J Med Chem       Date:  2020-03-02       Impact factor: 7.446

9.  Assessing mathematical models of influenza infections using features of the immune response.

Authors:  Hana M Dobrovolny; Micaela B Reddy; Mohamed A Kamal; Craig R Rayner; Catherine A A Beauchemin
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Estimation of the relative sensitivity of qPCR analysis using pooled samples.

Authors:  Ana Muniesa; Chelo Ferreira; Héctor Fuertes; Nabil Halaihel; Ignacio de Blas
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.